In Vivo Synthetic Anticancer Approach by Resourcing Mouse Blood Albumin as a Biocompatible Artificial Metalloenzyme
Angewandte Chemie International Edition · 2024
DOI: 10.1002/anie.202411225 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, 2024. Verfasst von Kyosuke Imai und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Science and Engineering, School of Materials and Chemical Technology, Tokyo Institute of Technology, 2-12-1 Ookayama, Meguro, …. Hauptthemen laut MEDLINE: Antineoplastic Agents, Serum Albumin. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development, Astellas Foundation for Research on Metabolic Disorders, Mizutani Foundation for Glycoscience.
Abstract (Originalsprache)
Methods for producing drugs directly at the cancer site, particularly using bioorthogonal metal catalysts, are being explored to mitigate the side effects of therapy. Albumin‐based artificial metalloenzymes (ArMs) catalyze reactions in living mice while protecting the catalyst in the hydrophobic pocket. Here, we describe the in situ preparation and application of biocompatible tumor‐targeting ArMs using circulating albumin, which is abundant in the bloodstream. The ArM was formed using blood albumin through the intravenous injection of ruthenium conjugated with an albumin‐binding ligand; the tumor‐targeting unit was conjugated to the ArM using its catalytic activity, and the ArM was transported to the cancer site. The delivered ArM catalyzed a second tagging reaction of the proapoptotic peptide on the cancer surface, successfully suppressing cancer proliferation. This approach, which efficiently leveraged the persisting reactivity twice in vivo, holds promise for future in vivo metal‐catalyzed drug synthesis utilizing endogenous albumin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemical Science and Engineering, School of Materials and Chemical Technology, Tokyo Institute of Technology, 2-12-1 Ookayama, Meguro, Tokyo, 152-8552, Japan.
- Biofunctional Synthetic Chemistry Laboratory, Cluster for Pioneering Research, RIKEN, 2-1 Hirosawa, Wako, Saitama, 351-0198, Japan.
- Laboratory for Chemistry and Life Science, Tokyo Institute of Technology, R1-11, 4259 Nagatsuta-cho, Midori-ku, Yokohama, Kanagawa, 226-8503, Japan.
ORCID-Profile: Kyosuke Imai, Kyohei Muguruma, Tsung-Che Chang, Ambara R Pradipta, Katsunori Tanaka
Förderung
- Japan Agency for Medical Research and Development
- Astellas Foundation for Research on Metabolic Disorders
- Mizutani Foundation for Glycoscience
- JSPS KAKENHI Grant
Zitieren
APA
Imai, K., Muguruma, K., Nakamura, A., Kusakari, Y., Chang, T. C., Pradipta, A. R., & Tanaka, K. (2024). In Vivo Synthetic Anticancer Approach by Resourcing Mouse Blood Albumin as a Biocompatible Artificial Metalloenzyme. Angewandte Chemie International Edition. https://doi.org/10.1002/anie.202411225
Vancouver
Imai K, Muguruma K, Nakamura A, Kusakari Y, Chang TC, Pradipta AR, et al. In Vivo Synthetic Anticancer Approach by Resourcing Mouse Blood Albumin as a Biocompatible Artificial Metalloenzyme. Angewandte Chemie International Edition. 2024. doi:10.1002/anie.202411225
BibTeX
@article{Imai2024,
author = {Imai, Kyosuke and Muguruma, Kyohei and Nakamura, Akiko and Kusakari, Yuriko and Chang, Tsung-Che and Pradipta, Ambara R and Tanaka, Katsunori},
title = {In Vivo Synthetic Anticancer Approach by Resourcing Mouse Blood Albumin as a Biocompatible Artificial Metalloenzyme},
journal = {Angewandte Chemie International Edition},
year = {2024},
doi = {10.1002/anie.202411225}
}
EUVIMED